565. Morbi-mortality in patients with proved Mycobacterium tuberculosis infetions,  co-infected and no co-infected with VIH, at Roosevelt Hospital in Guatemala
Session: Poster Abstract Session: Clinical Tuberculosis: Trends and Experiences
Thursday, October 8, 2015
Room: Poster Hall

Tuberculosis (TB) is the main opportunistic infection related to HIV, causing complex and serious disease, frequently,  extra-pulmonary in HIV patients. In Guatemala it represents the main cause of death in AIDS patients and with an increased incidence in patients with other co-morbidities. 


Objective: To determine the morbimortaily in admitted patients with tuberculosis at Roosevelt Hospital in Guatemala City.

Patients with proved infection by culture positive to Mycobacterium tuberculosis were included, older than 12 years old, admitted to the internal medicine guards, that presented positive culture or ZN smears and/or GeneXpert positive tests in 2013. Clinical and epidemiological data were colected in a prospective manner, with an standarized instrument, generating an Excel 2010 data base that was analized by SPSS21.  


200 patients were included, 61% males with man:woman ratio of 1.5:1. 48% presented HIV coinfection. 54% of the patients aged: 25 to 44 years old. 43% residents outside  Guatemala City. The extrapulmonary TB was present in 65%. The highest mortality was observed in TB-HIV coinfected patients: 30.2% (p=0.001), 2.1% of them died before 24 hours, 13.5% between 1-7 days; 14.6% after 7 days of hospital stay, (p=0.002). Regarding the CD4 count, the higher mortality index was shown in the cases <100cel/mL 24.91% (p=0.0001).


In a reference center like  Roosevelt Hospital, the coinfection HIV-TB represents the  half of the cases. Probably thanks fo the availability  of high technology diagnose methods that allow to confirm the extrapulmonary cases as it relates to a 30% mortality.

Carlos Mejia-Villatoro, MD, Internal Medicine, Clinica de Enfermedades Infecciosas, Hospital Roosevelt, Guatemala, Guatemala and Nereyda De Leon MD, Remei Gordillo QB, Andre Choco Pharm


C. Mejia-Villatoro, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.